GBY Stock Chart & Stats
€0.21
-€0.20(-3.81%)
At close: 4:00 PM EDT
€0.21
-€0.20(-3.81%)
Day’s Range― - ―
52-Week Range€0.04 - €0.63
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
€16.37M
Enterprise Value€65.70M
Total Cash (Recent Filing)€27.59M
Total Debt (Recent Filing)€19.33M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding414,288,850
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.25
Price to Sales (P/S)2.98
P/FCF Ratio-1.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.76Price Target Upside735.91% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.25
Revenue Forecast (FY)€8.76M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress For ST‑920 (Fabry)FDA alignment on an accelerated approval endpoint and allowance of 104‑week data as confirmatory materially reduces regulatory uncertainty for ST‑920. This structural clarity improves the asset’s de‑risking profile and increases the prospect that a completed BLA could be monetized or approved if data remain favorable.
Platform And Scientific VisibilityMultiple conferences and reported advances in zinc‑finger regulation and MINT targeted integration demonstrate durable IP and technical differentiation. Persistent platform strength supports long‑term partner interest, licensing, or acquisition value independent of short‑term financing noise.
High Gross Margins On Reported RevenueSustained high gross margins indicate core scientific outputs have low direct COGS, meaning any successful commercialization or licensing could be highly profitable. This structural margin profile enhances long‑term economics for acquirers or partners even though operating losses persist today.
Bears Say
Chapter 11 Filing And Asset‑sale ProcessChapter 11 and proposed asset sales represent a fundamental strategic reset that likely transfers key technologies and pipeline value to buyers. This restructures long‑term ownership of core assets, disrupts execution continuity, and greatly diminishes the standalone equity claim on future clinical upside.
Persistent Heavy Cash Burn And Negative EquitySustained ~‑$90M annual cash burn and negative equity materially constrain optionality. Structural funding needs force reliance on financing, asset sales, or partner deals to continue operations or complete regulatory submissions, raising dilution and execution risk over the medium term.
Revenue Dependent On Collaborations And MilestonesA business model driven by upfronts and milestones yields lumpy, partner‑dependent cash flows and no recurring product revenue. Long‑term viability therefore hinges on successful partner advancement, licensing, or asset monetization rather than steady internal commercialization.
Sangamo Therapeutics News
GBY FAQ
What was Sangamo Therapeutics’s price range in the past 12 months?
Sangamo Therapeutics lowest stock price was €0.04 and its highest was €0.63 in the past 12 months.
What is Sangamo Therapeutics’s market cap?
Sangamo Therapeutics’s market cap is €16.37M.
When is Sangamo Therapeutics’s upcoming earnings report date?
Sangamo Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 43 days.
How were Sangamo Therapeutics’s earnings last quarter?
Sangamo Therapeutics released its earnings results on May 14, 2026. The company reported -€0.069 earnings per share for the quarter, missing the consensus estimate of €0.004 by -€0.074.
Is Sangamo Therapeutics overvalued?
According to Wall Street analysts Sangamo Therapeutics’s price is currently Undervalued.
Does Sangamo Therapeutics pay dividends?
Sangamo Therapeutics does not currently pay dividends.
What is Sangamo Therapeutics’s EPS estimate?
Sangamo Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Sangamo Therapeutics have?
Sangamo Therapeutics has 414,288,850 shares outstanding.
What happened to Sangamo Therapeutics’s price movement after its last earnings report?
Sangamo Therapeutics reported an EPS of -€0.069 in its last earnings report, missing expectations of €0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sangamo Therapeutics?
Currently, no hedge funds are holding shares in DE:GBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sangamo Therapeutics
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation to achieve its objectives. A cornerstone of Sangamo's approach is its proprietary zinc finger protein (ZFP) technology platform. This platform facilitates the creation of zinc finger nucleases, which are specialized proteins capable of precisely altering DNA sequences by either inserting or inactivating specific genes. Furthermore, it produces ZFP transcription factors, proteins designed to modulate (increase or decrease) gene expression. Sangamo has a robust clinical pipeline, with key programs progressing through various stages. SB-525 is currently in the Phase III AFFINE clinical trial for the treatment of hemophilia A. Their gene therapy candidate, ST-920, is undergoing Phase I/II STAAR clinical trials for Fabry disease, while the cell therapy SAR445136 is being evaluated in Phase I/II PRECIZN-1 clinical trials for sickle cell disease. The company's development efforts also extend to other therapeutic areas, including TX200, a chimeric antigen receptor for addressing HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy targeting cancer; ST-501 for tauopathies; and ST-502, which is aimed at treating synucleinopathies like Parkinson's disease and other neuromuscular disorders. Sangamo has established numerous collaborative and strategic partnerships with leading entities such as Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and the California Institute for Regenerative Medicine. Established in 1995, the company was initially known as Sangamo BioSciences, Inc. It subsequently adopted its current name, Sangamo Therapeutics, Inc., in January 2017. The corporate headquarters are situated in Brisbane, California.
GBY Company Deck
GBY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights meaningful clinical and regulatory progress for ST-920 (rolling BLA, FDA affirmation of 2-year confirmatory endpoint, durable long-term patient data) and continued advancement across neurology programs and platform technologies. However, material near-term risks center on capital availability and a NASDAQ delisting determination that forced a transition to the OTCQB market. Progress on regulatory and scientific fronts is balanced by significant financing and market-listing challenges that could impact execution and timing.View all DE:GBY earnings summariesGBY Stock 12 Month Forecast
Average Price Target
€1.76
▲(735.91% Upside)
Technical Analysis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Options Prices
Currently, No data available
---